Physician profile
Mark A Weisbrod
NPI 1316141914
$3,048.04
in general payments reported to CMS, 2019-2025
6 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $350 · 2021: $58.65 · 2022: $384 · 2023: $34.84 · 2024: $38.88 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,907.40 | 2019-2025 | Lensx, Argos, Clareon |
| Vertex Pharmaceuticals Incorporated | $694.00 | 2020-2022 | |
| Glaukos Corporation | $375.80 | 2025 | Idosetr, Istent Infinite |
| Novartis Pharmaceuticals Corporation | $37.12 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $19.52 | 2025 | |
| Oyster Point Pharma, INC. | $14.20 | 2024 | Tyrvaya, Ryzumvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weisbrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.